60 Degrees Pharmaceuticals Announces Exclusive Option Agreement with Florida State University to Advance Castanospermine for Tick-Borne Diseases

License expands collaboration with Florida State University to evaluate castanospermine for Powassan virus disease, tick-borne encephalitis, alpha-gal syndrome, and post-treatment Lyme disease Agreement builds on Company's expertise in vector-borne diseases and complements ongoing development of

July 8, 2026 | Read More

60 Degrees Pharmaceuticals Announces Positive Recommendation from Data Safety Monitoring Board for B-FREE Phase 2 Study of Tafenoquine for Treatment of Chronic Babesiosis Patients with Severe Fatigue

Independent DSMB identifies no safety concerns and recommends continuation of the clinical trial being conducted at the Icahn School of Medicine at Mount Sinai WASHINGTON, July 01, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.  (NASDAQ: SXTP; SXTPW) (“60 Degrees…

July 1, 2026 | Read More

60 Degrees Pharmaceuticals Signs Exclusive Patent License Agreement with Florida State University for Non-Prescription Use of Australian Chestnut Extract as a Botanical Supplement

License allows the Company to commence large-scale extraction of castanospermine from the seeds of  Castanospermum australe Company will meet with FDA on July 1, 2026, to discuss Non-Notified Letter issued by the Agency in response to the Company’s recent New…

June 11, 2026 | Read More

60 Degrees Pharmaceuticals Announces Early Enrollment of First Seasonal Patient in Clinical Trial of Tafenoquine for Patients Hospitalized with Babesiosis

Enrollment is tracking ahead of schedule, allowing potential acceleration of key trial milestones Minimum enrollment to support interim analysis expected as soon as early July 2026 Randomized, double-blind, placebo-controlled trial is evaluating the efficacy and safety of  tafenoquine  in treating

May 26, 2026 | Read More

60 Degrees Pharmaceuticals Announces First Quarter 2026 Results

WASHINGTON, May 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.  (NASDAQ:  SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today reported its financial results for the first quarter of fiscal year 2026,…

May 15, 2026 | Read More

60 Degrees Pharma Announces ARAKODA (tafenoquine) for Malaria Prevention is Now Available on Runway Health Travel Website

Travelers can now purchase the only once-weekly, broad-spectrum malaria preventive online, through the Runway Health telehealth platform WASHINGTON, April 15, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical

April 15, 2026 | Read More

60 Degrees Pharmaceuticals Announces 2025 Annual Results

FY 2025 net product revenues increased 65% to $1,005,000 Current shelf capacity exhausted after raise of $4 million through an ATM facility WASHINGTON, March 31, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.   (NASDAQ: SXTP; SXTPW) (the “Company”), a…

March 31, 2026 | Read More

60 Degrees Pharmaceuticals Files New Dietary Ingredient Notification (NDIN) with FDA for Australian Chestnut Extract

FDA has until May 25, 2026 to object to the notification, after which the Company will be free to market its proposed dietary supplement containing Australian Chestnut Extract Company has signed an option agreement with Florida State University (FSU) to…

March 18, 2026 | Read More

60 Degrees Pharmaceuticals Announces All Patients Cured of Babesiosis After Tafenoquine Treatment in Expanded Use Clinical Trial

All three patients enrolled in study have been cured, confirming high cure rate of  tafenoquine in immunosuppressed patients, as reported by Yale in a 2024 publication Company calls for existing babesiosis treatment guidelines to be reviewed in light of the…

March 11, 2026 | Read More

60 Degrees Pharmaceuticals Expands Access to ARAKODA® with GoodRx Partnership

GoodRx to offer prescription savings of up to 30% for ARAKODA ® ( tafenoquine) Collaboration designed to lower patient out-of-pocket costs and expand the reach of Company’s marketing strategy Partnership will improve the affordability of ARAKODA at over 70,000 pharmacies nationwide…

February 2, 2026 | Read More

60 Degrees Pharmaceuticals Exercises License Option with Florida State University for Large-Scale Purification of Castanospermine for Non-Rx Use

Company ready to commence regulatory process to secure access to U.S. market for Australian Chestnut Extract as a botanical product for non-prescription uses WASHINGTON, Jan. 28, 2026 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.  (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma”…

January 28, 2026 | Read More

60 Degrees Pharmaceuticals Announces Partnership with Runway Health to Provide International Travelers Direct Access to ARAKODA® for Malaria Prevention

Partnership adds a travel-focused consumer telehealth platform to the ARAKODA ® marketing strategy, offering a new convenience to people planning travel to malaria-endemic regions of the world ARAKODA is the only FDA-approved, broad spectrum, once-weekly malaria prevention option for international

January 22, 2026 | Read More

60 Degrees Pharmaceuticals, Inc. Announces Approval of Reverse Stock Split Ratio

WASHINGTON , Jan. 15, 2026 (GLOBE NEWSWIRE) -- 60 Degree Pharmaceuticals, Inc. NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne disease, today announced that it will effect a one-for-four…

January 15, 2026 | Read More

60 Degrees Pharmaceuticals Announces Detection of Babesia Infection in 24 Percent of Patients Presenting with Chronic Fatigue in Peer-Reviewed, Sponsored Study at NC State

Further validates continuation of the B-FREE Study to evaluate the efficacy and safety of ARAKODA ® ( tafenoquine ) for treatment of chronic babesiosis Data support theory among specialists that Babesia infection may prolong recovery times in patients with chronic…

December 29, 2025 | Read More

60 Degrees Pharmaceuticals Announces Expansion of ARAKODA® Sales and Marketing in 2026

6-month commercial pilot demonstrated increasing demand among prescribers Expansion plan includes doubling the number of sales reps, a new GoodRx partnership, and enhanced digital marketing campaign Additional clinical sites in ongoing babesiosis treatment trials will be initiated in light of…

December 11, 2025 | Read More

60 Degrees Pharmaceuticals Announces Clinical Site Now Open for Patient Enrollment for the B-FREE Chronic Babesiosis Study at Mount Sinai Icahn School of Medicine

90-day trial will measure change in general fatigue in patients with chronic babesiosis following  tafenoquine treatment Study will run approximately 12 months and enroll up to 100 patients Internal estimates of the unmet medical need are between 4,400 and 190,000…

November 21, 2025 | Read More

60 Degrees Pharmaceuticals Announces Third Quarter 2025 Results

Q3 2025 net product revenue increased 223% year-over-year to $438 thousand Gross profit/(loss) decreased from $24 thousand to $(100) thousand WASHINGTON , Nov. 13, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical…

November 13, 2025 | Read More

60 Degrees Pharmaceuticals Announces No Detection of Babesia Infection in First Patient Following Treatment with Tafenoquine in Relapsing Babesiosis Study

Breakthrough Therapy Designation request has been submitted to FDA Company to request a Type B meeting with FDA in early 2026 to discuss requirements for a supplementary New Drug Application (sNDA) Results obtained using highest sensitivity test available; licensed by…

October 15, 2025 | Read More

60 Degrees Pharmaceuticals Unveils Name of Chronic Babesiosis Clinical Trial: B-FREE Chronic Babesiosis Study

Company engaged patients diagnosed with chronic babesiosis via social media in a nationwide naming competition A $5K donation from the Company was split between ILADEF and GLA to recognize the winning name B-FREE, a Phase 2 trial, will commence in…

October 9, 2025 | Read More

60 Degrees Pharmaceuticals Live Webcast Link and New Date for Presentation at H.C. Wainwright 27th Annual Global Investment Conference

WASHINGTON , Sept. 03, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today the webcast link and change of…

September 3, 2025 | Read More

60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

WASHINGTON , Aug. 21, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharma” or the “Company”), a pharmaceutical company focused on developing new medicines for vector-borne diseases, announced today it will participate in the H.C.

August 21, 2025 | Read More

60 Degrees Pharmaceuticals Selects Icahn School of Medicine at Mount Sinai as Central Clinical Trial Site for Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

90-day trial measuring change in general fatigue in chronic babesiosis patients Enrollment expected to commence Q4 2025 and to be completed by Q2 2026 Site has clinical expertise in infectious disease trials and access to a robust patient population with…

August 19, 2025 | Read More

60 Degrees Pharmaceuticals Announces Second Quarter 2025 Results

A now resolved supply disruption led to Q2 net product revenue decline but higher profitability due to increased usage of a cash-pay distribution model $1.97 million cash on hand, runway through March 31, 2026 WASHINGTON , Aug. 13, 2025 (GLOBE…

August 13, 2025 | Read More

60 Degrees Pharmaceuticals and Tulane University Sign Research Agreement to Study Tafenoquine Against Lyme and Bartonella Bacteria

Study will evaluate activity of tafenoquine against vector-borne pathogens, Borrelia (Lyme disease) and Bartonella in cell culture Borrelia and Bartonella , together with Babesia , represent the "3Bs," pathogens most often present in individuals with tick-borne illness such as Lyme…

July 17, 2025 | Read More

60 Degrees Pharmaceuticals Announces Closing of up to $10 Million Public Offering

$5 million received upfront with up to an additional $5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants WASHINGTON , July 16, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (the “Company” or “60…

July 16, 2025 | Read More

60 Degrees Pharmaceuticals Announces Pricing of Up to $10 Million Public Offering

$5 million upfront with up to an additional $5 million of potential aggregate gross proceeds upon the exercise in full of short-term warrants WASHINGTON , July 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (the “Company” or “60 Degrees”)…

July 15, 2025 | Read More

60 Degrees Pharmaceuticals Defines Potential Human Babesiosis Market Size for ARAKODA® (tafenoquine): Annual Max TAM, Sales of $245 Million; Cumulative through Patent Expiration, $1.1 Billion

New Drug Application intended for 2026, subject to generation of positive data from three U.S. clinical trials planned or in progress Total addressable market (TAM) for ARAKODA for Human Babesiosis is informed by results of a 6,000 nationwide patient survey…

July 15, 2025 | Read More

60 Degrees Pharmaceuticals to Submit MUMS (Minor Use/Minor Species) Designation Request to FDA for Tafenoquine for Acute Canine Babesiosis in 2025

Data from three independent clinical studies demonstrate utility of tafenoquine to treat acute canine babesiosis WASHINGTON , July 14, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.  (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on…

July 14, 2025 | Read More

60 Degrees Pharmaceuticals Expands Options for Malaria Prevention with Introduction of ARAKODA® (tafenoquine) 8-Count Bottle Format

New 8-count bottles now available through major retail pharmacies ARAKODA® is the only weekly prophylactic therapy to provide protection against the blood and liver stages of malaria WASHINGTON , June 04, 2025 (GLOBE NEWSWIRE) --   60 Degrees Pharmaceuticals, Inc.

June 4, 2025 | Read More

Babesiosis Incidence in U.S. 10x Higher Than CDC Estimates, According to Insurance Claims Study Commissioned by 60 Degrees Pharmaceuticals

25,000 U.S. adults per year claim reimbursement for medical costs associated with babesiosis v. CDC estimates of 2,000 A full 45 percent of persistent babesiosis cases include chronic fatigue Healthcare providers treating patients who present with unexplained chronic fatigue may…

June 3, 2025 | Read More

60 Degrees Pharmaceuticals Announces First Quarter 2025 Results

Q1 2024 net product revenues increased 55% year-over-year to $163.6 thousand. Gross profit increased 124% to $90.3 thousand. WASHINGTON , May 15, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc.  (NASDAQ:  SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on…

May 15, 2025 | Read More

Babesiosis Disease Burden in United States is Substantially Higher Than Official Estimates, According to Preliminary Results of 60 Degrees Pharma Survey

In a survey representative of the general U.S. adult population, 1.26 percent of respondents – equivalent to about 3 million people – reported having received a medical diagnosis of babesiosis during their life-time; CDC data imply only about 73,000 people…

April 22, 2025 | Read More

Geoff Dow, PhD, Infectious Disease Product Development Expert, to Discuss Babesiosis at Healing Lyme Summit, April 15-21

WASHINGTON , April 10, 2025 (GLOBE NEWSWIRE) -- Geoff Dow , infectious disease product development expert and chief executive officer of 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), will participate in a scientific discussion on…

April 10, 2025 | Read More

Sixty Degrees Pharmaceuticals Announces Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention with Yale School of Medicine and Yale School of Public Health

WASHINGTON, D.C. , April 08, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the signing of a Patent License…

April 8, 2025 | Read More

60 Degrees Pharmaceuticals Announces 2024 Annual Results

FY 2024 net product revenues increased 140% to $607.6 thousand . FY 2024 gross profit increased $443.8 thousand from ( $221 thousand ) to $222.8 thousand . WASHINGTON , March 28, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.  (NASDAQ:…

March 28, 2025 | Read More

60 Degrees Pharmaceuticals, Inc. Announces 1:5 Reverse Stock Split

WASHINGTON , Feb. 20, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it will effect a 1-for-5 reverse stock split (“Reverse…

February 20, 2025 | Read More

Sixty Degrees Pharmaceuticals to Ensure Continuity of Tafenoquine Supply in U.S. by Importing Limited Quantity of KODATEF®

WASHINGTON , Feb. 11, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), pharmaceutical company today announced that the United States Food and Drug Administration (FDA) does not object to the Company’s plan…

February 11, 2025 | Read More

60 Degrees Pharma Announces Closing of $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

Raised approximately $2.118 million in gross proceeds since the beginning of 2025 WASHINGTON , Feb. 06, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases,…

February 6, 2025 | Read More

60 Degrees Pharma Announces $1.075 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WASHINGTON , Feb. 05, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that it has entered into definitive agreements for the purchase…

February 5, 2025 | Read More

60 Degrees Pharma Announces Closing of $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WASHINGTON , Jan. 30, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the closing of its previously announced registered direct offering priced

January 30, 2025 | Read More

60 Degrees Pharma Announces $1.043 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules

WASHINGTON , Jan. 29, 2025 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that it has entered into definitive agreements for the purchase…

January 29, 2025 | Read More

60 Degrees Pharma Announces IRB Approval of Phase II Study to Evaluate Tafenoquine for Chronic Babesiosis

Investigational Review Board (IRB) approval has been granted for the open-label study to evaluate tafenoquine for treatment of patients with a presumptive diagnosis of chronic babesiosis in outpatient settings. Enrollment expected to commence Q3 2025. WASHINGTON , Jan.

January 28, 2025 | Read More

60 Degrees Pharmaceuticals Enrolls First Patient in Tafenoquine Expanded Access Clinical Study for Persistent (B. microti) Babesiosis

Case reports published in medical literature suggest that tafenoquine combined with standard-of-care treatment exhibits a high cure rate in immunosuppressed patients who have relapsing babesiosis and for whom prior treatment has failed. Babesiosis, a tick-borne disease, is potentially

January 8, 2025 | Read More

Sixty Degrees Pharmaceuticals and Tufts Medical Center Announce Patent License Agreement to Advance Development of Tafenoquine for Babesiosis Treatment and Prevention

WASHINGTON , Dec. 23, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees” or the “Company”), pharmaceutical company, and Tufts Medical Center (“Tufts MC”), a leading academic medical center, today announced the signing of a Patent…

December 23, 2024 | Read More

60 Degrees Pharmaceuticals Expands Tafenoquine Clinical Trial for Babesiosis to Brigham and Women’s Hospital

The trial (NCT06207370) evaluates tafenoquine combined with standard treatment for babesiosis, addressing a critical unmet medical need. The clinical site is led by Brigham and Women’s Hospital researchers Ann Woolley , M.D., and David Leaf , M.D. The double-blind, placebo-controlled…

December 11, 2024 | Read More

60 Degrees Pharmaceuticals Announces Third Quarter 2024 Results

Q3 2024 sales revenue increased 164% year-over-year to $135 thousand . Sequential (quarter-over-quarter) net product revenue growth of 8.3%. Gross profit increased from ( $20 thousand ) to $24 thousand . WASHINGTON , Nov. 14, 2024 (GLOBE NEWSWIRE) -- 60…

November 14, 2024 | Read More

60 Degrees Pharmaceuticals Inc. Announces ARAKODA® Promotional Pilot in Advance of Expanded U.S. Launch

Highlights include increased ARAKODA ® ( tafenoquine ) brand awareness and utilization through virtual sales outreach using digital behavioral analytics and a co-pay program to assist consumers with out-of-pocket costs. ARAKODA is the only new antimalarial in over a decade…

October 3, 2024 | Read More

60 Degrees Pharmaceuticals, Inc. Announces Closing of $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

WASHINGTON , Sept. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced the closing of its previously announced private placement,…

September 6, 2024 | Read More

60 Degrees Pharmaceuticals, Inc. Announces $4 Million Private Placement Priced At-the-Market Under Nasdaq Rules

WASHINGTON , Sept. 04, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that it has entered into definitive agreements for…

September 4, 2024 | Read More

60 Degrees Pharmaceuticals, Inc. Regains Compliance with Nasdaq Listing Requirements

WASHINGTON , Aug. 28, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that on August 26, 2024 it received written notice…

August 28, 2024 | Read More

60 Degrees Pharmaceuticals Announces Second Quarter 2024 Results

Q2 2024 net product revenues doubled year-over-year to $125 thousand Sequential (quarter-over-quarter) net product revenue growth of 18.3% Gross profit increased from ( $124 thousand ) to $35 thousand , year-over-year WASHINGTON , Aug. 14, 2024 (GLOBE NEWSWIRE) -- 60…

August 14, 2024 | Read More

60 Degrees Pharma Provides University of Kentucky with Right of Reference to ARAKODA® NDA in Support of SJ733 Phase IIb Study

University of Kentucky will commence a Phase IIb clinical study of drug development candidate SJ733 for treatment of vivax malaria. SJ733 will be combined with a single dose of tafenoquine in the study. The right of reference allows FDA to…

August 12, 2024 | Read More

60 Degrees Pharmaceuticals, Inc. Announces 1:12 Reverse Stock Split

WASHINGTON , Aug. 06, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that it will effect a 1-for-12 reverse stock split (“Reverse…

August 6, 2024 | Read More

60 Degrees Pharmaceuticals Awarded Contract with U.S. Army for ARAKODA® Supply Chain Upgrade Support

60 Degrees Pharmaceuticals has been awarded a contract with the United States Army Medical Materiel Development Activity to facilitate commercial validation of new bottle and replacement blister packaging of ARAKODA ® ( tafenoquine ), the Company’s FDA-approved product indicated for…

July 25, 2024 | Read More

60 Degrees Pharmaceuticals Signs Clinical Trial Agreements With All Planned Trial Sites for Tafenoquine Babesiosis Study

The Tafenoquine for Babesiosis clinical trial will be conducted at three sites: Yale University , Rhode Island Hospital and Tufts Medical Center Patient enrollment has begun; interim results anticipated by September, 2025 In the Northeast U.S. , the incidence of…

July 19, 2024 | Read More

60 Degrees Pharma Announces IRB Approval of Clinical Study of Tafenoquine for Treatment of Babesiosis in Immunocompromised Patients with Persistent Babesia microti Despite Prior Treatment

WASHINGTON , July 09, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP; SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced ethics approval of an open label,…

July 9, 2024 | Read More

First Patient Enrolled in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis at Tufts Medical Center; First and Only Study of Its Kind

The efficacy and safety of tafenoquine in treating human babesiosis will be evaluated in a randomized, double-blind, placebo-controlled trial conducted at Tufts Medical Center in Boston . Endpoints are time to sustained clinical resolution of symptoms of babesiosis, and molecular…

June 27, 2024 | Read More

60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis

With the tafenoquine for acute babesiosis orphan drug designation, 60 Degrees Pharmaceuticals now qualifies for certain incentives, including market exclusivity, tax credits, and exemption from certain FDA filing fees. 60 Degrees Pharmaceuticals recently announced it has entered into an agreement

June 11, 2024 | Read More

Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind

60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct a clinical trial that will evaluate the safety and efficacy of tafenoquine for the treatment of babesiosis in humans The study will be the world’s first clinical…

May 30, 2024 | Read More

60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study

Long-term chronic fatigue syndrome (CFS) symptoms can be triggered by certain prior acute infections Prominent researchers/clinicians in the tick-borne disease scientific community postulate that latent  Babesia spp infections may trigger CFS symptoms Planned study at North Carolina State College

May 20, 2024 | Read More

60 Degrees Pharmaceuticals Announces First Quarter 2024 Results

Q1 2024 net product revenues increased 515% year-over-year to $105.7 thousand . Gross profit increased from ( $55.9 thousand ) to $51.0 thousand . WASHINGTON , May 15, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.   (NASDAQ: SXTP ;…

May 15, 2024 | Read More

60 Degrees Pharmaceuticals Outlines Upcoming Clinical Trial of Tafenoquine in Babesiosis in Letter to Journal of Infectious Diseases

The U.S. medical scientific community is calling for clinical studies to expand shared understanding of babesiosis, an emerging tick-borne illness. The upcoming 60 Degrees Pharma clinical trial of tafenoquine in treating babesiosis will be the first and only such study…

May 8, 2024 | Read More

60 Degrees Pharmaceuticals Receives FDA Comments on Tafenoquine-Babesiosis Clinical Trial Protocol; No Material Changes Required

Trial planning and execution to proceed as planned WASHINGTON , May 02, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.  (NASDAQ: SXTP ; SXTPW) (the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that…

May 2, 2024 | Read More

60 Degrees Pharmaceuticals to Sponsor Pilot Study of Tafenoquine for Treatment of Canine Babesiosis

Study to be conducted by North Carolina State University in 2024 Standard of care fails in 20 percent of cases and drug resistance is a problem Standard of care is expensive WASHINGTON , April 03, 2024 (GLOBE NEWSWIRE) -- 60…

April 3, 2024 | Read More

60 Degrees Pharmaceuticals Announces Communication from the FDA of Intention to Respond to Tafenoquine-Babesiosis Trial Protocol Submission in April, 2024

WASHINGTON , March 14, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. , (NASDAQ: SXTP , SXTPW) (“60 Degrees Pharmaceuticals” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, today announced that the U.S.

March 14, 2024 | Read More

60 Degrees Pharmaceuticals to Sponsor Pre-Clinical Studies of Tafenoquine Use in Candida spp, Including Candida auris

Candida auris (C. auris) is a dangerous drug-resistant fungal pathogen emerging in U.S. hospitals Tafenoquine ’s presumed mode of action against C. auris is differentiated from standard of care treatment Monash University will conduct the studies beginning in second quarter…

February 20, 2024 | Read More

60 Degrees Pharmaceuticals Appoints Kristen Landon as Chief Commercial Officer

To lead U.S. commercial relaunch of ARAKODA® (tafenoquine) for malaria prevention Will support Company plan to expand clinical research strategy in tick-borne diseases beyond acute babesiosis WASHINGTON , Feb. 08, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc.

February 8, 2024 | Read More

60 Degrees Pharmaceuticals Announces Closing of $2.4 Million Public Offering

WASHINGTON , Jan. 31, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. ( NASDAQ: SXTP; SXTPW ) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medicines for the treatment and prevention of infectious diseases, announced…

January 31, 2024 | Read More

60 Degrees Pharmaceuticals Announces Pricing of $2.4 Million Public Offering

WASHINGTON , Jan. 30, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc. ( NASDAQ: SXTP; SXTPW ) (“60 Degrees Pharmaceuticals” or the “Company”), specialists in developing and marketing new medicines for the treatment and prevention of infectious diseases, announced…

January 30, 2024 | Read More

60 Degrees Pharma Plans Pivotal Babesiosis Study with Tafenoquine Following Jan 17 FDA Meeting

Following a Type C meeting with FDA on January 17, 2024 , 60 Degrees Pharma (60P) now plans to conduct a pivotal clinical study in support of a future indication for tafenoquine for treatment of hospitalized babesiosis patients Patient enrollment…

January 22, 2024 | Read More

60 Degrees Pharma Regains Compliance with Nasdaq Listing Requirements

WASHINGTON , Jan. 16, 2024 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals, Inc. (NASDAQ: SXTP ; SXTPW) (“60P” or the “Company”), a pharmaceutical company focused on developing new medicines for infectious diseases, announced today that on January 10, 2024 it received…

January 16, 2024 | Read More

60 Degrees Pharma Announces IRB Approval of Phase IIA Study to Evaluate Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease; Type C Meeting Re-Scheduled by FDA to January 17, 2024

 Investigational Review Board (IRB) approval has been granted for 60 Degrees Pharma’s double-blind, placebo-controlled study to investigate tafenoquine for treatment of hospitalized babesiosis patients The previously announced Type C meeting with FDA has been rescheduled by FDA from January 15…

December 26, 2023 | Read More

60 Degrees Pharma Announces Type C Meeting with FDA to Discuss Development of Tafenoquine for Babesiosis, an Emerging Tick-Borne Disease

Type C meeting will be to discuss a proposed Phase II study of tafenoquine for treatment of babesiosis Transmitted by ticks, babesiosis is a life-threatening parasitic disease increasing in frequency in the United States Meeting with FDA scheduled for January…

November 15, 2023 | Read More

60 Degrees Pharma to Present Review of Safety, Efficacy Data of 8-Aminoquinolines for Malaria and Babesiosis Treatment at ILADS Annual Scientific Meeting in Boston

60 Degrees Pharmaceuticals will present scientific poster on new, long-term safety data on the use of tafenoquine for malaria prevention at the ILADS 2023 annual scientific meeting 60 Degrees Pharmaceuticals will also present a comprehensive review of the scientific literature…

October 19, 2023 | Read More

60 Degrees Pharmaceuticals Suspends Phase IIB Study of Tafenoquine for COVID-19, Pivots to Refocus on Commercialization of Treatments for Malaria and Tick-Borne Diseases

FDA advice to Company suggested execution of ACLR8-LR, a placebo-controlled Phase IIB study of tafenoquine in COVID-19 patients, may not be feasible in the U.S. Company will therefore focus efforts on further commercialization related to ARAKODA ®  ( tafenoquine )…

October 12, 2023 | Read More

60 Degrees Pharma Withdraws COVID Phase IIB IND, Will Resubmit Pending Assessment of Ability to Meet FDA Requirements

Prompted by advice from FDA regarding study design, 60P Australia Pty Ltd , a majority-owned subsidiary of 60 Degrees Pharmaceuticals , has withdrawn its IND for ACLR8-LR, a Phase IIB study of the use of tafenoquine in treating COVID-19; Company…

September 18, 2023 | Read More

60 Degrees Pharmaceuticals to Participate in H.C. Wainwright 25th Annual Global Investment Conference

Management investor presentation webcast available Monday 9/11, 7:00 AM ET Attendees may request 1 x 1 meetings with management at meetings@hcwco.com WASHINGTON , Sept. 06, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals Inc. (“60P” or the “Company”) (Nasdaq: SXTP ),…

September 6, 2023 | Read More

60 Degrees Pharmaceuticals Study Results Published by New Microbes and New Infections Demonstrate Tafenoquine Exhibits Broad Spectrum Antifungal Activity

Data showed tafenoquine does not exhibit cross-susceptibility with fluconazole against Candida spp. Effective treatment of drug-resistant Candida infections is an unmet need in U.S. market Presumed mode of action differentiated from standard of care treatment WASHINGTON , Aug.

August 30, 2023 | Read More

60 Degrees Pharmaceuticals Receives Additional U.S. Patent Covering Tafenoquine for Prevention of Plasmodium Falciparum Malaria

60P was awarded additional U.S. patent protection to further solidify its exclusive rights through 2035 for tafenoquine for prevention of Plasmodium falciparum malaria in naïve individuals Tafenoquine kills dormant liver stage of P. vivax  parasite and clears the blood stages…

August 22, 2023 | Read More

60 Degrees Pharmaceuticals Registers ACLR8-LR, a Phase IIB Study of Tafenoquine for Treatment of COVID-19, on ClinicalTrials.gov

ACLR8-LR, a double-blind, randomized, placebo-controlled Phase IIB study to determine efficacy of the ARAKODA ® regimen of tafenoquine in COVID-19 patients with mild-moderate symptoms and low risk of disease progression, has been registered on ClinicalTrials.gov 60P’s majority-owned subsidiary, 60P

August 15, 2023 | Read More

60 Degrees Pharmaceuticals Awarded Canadian Patent Covering Tafenoquine for Prevention of Malaria in Malaria-Naive Subjects

Patent provides exclusive use of tafenoquine for prevention of malaria in malaria-naive individuals in Canada until late 2035. Tafenoquine is the active molecule in 60 Degrees Pharmaceuticals’ USFDA-approved drug for malaria prevention, ARAKODA ® . Most travelers from Canada and…

July 31, 2023 | Read More

60 Degrees Pharmaceuticals and Unicycive Therapeutics Interviews to Air on Bloomberg TV on the RedChip Money Report(R)

ORLANDO, FL / ACCESSWIRE / July 21, 2023 /  RedChip Companies will air interviews with 60 Degrees Pharmaceuticals, Inc. (NASDAQ:SXTP) and Unicycive Therapeutics, Inc. (NASDAQ:UNCY) on The RedChip Money Report® on Bloomberg TV, this Saturday, July 22, at 7 p.m.…

July 21, 2023 | Read More

60 Degrees Pharmaceuticals Announces Closing of Initial Public Offering

WASHINGTON, July 14, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc., (NASDAQ: SXTP; SXTPW) (“60P” or the “Company”), specialists in developing and marketing medicines for infectious diseases, announced today the closing of its initial public offering of 1,415,095 units…

July 14, 2023 | Read More

WallachBeth Capital Announce Pricing Of 60 Degrees Pharmaceuticals IPO At $5.30 Per Unit

JERSEY CITY, N.J. , July 12, 2023 /PRNewswire/ -- WallachBeth Capital LLC , a leading provider of capital markets and institutional execution services, announced today that 60 Degrees Pharmaceuticals, Inc. , (NASDAQ: SXTP; SXTPW) specialists in developing and marketing medicines…

July 12, 2023 | Read More

60 Degrees Pharmaceuticals Announces Pricing of Initial Public Offering

WASHINGTON , July 12, 2023 (GLOBE NEWSWIRE) -- 60 Degrees Pharmaceuticals , Inc., (NASDAQ: SXTP; SXTPW) ("60P" or the "Company"), specialists in developing and marketing medicines for infectious diseases, announced today the pricing of its initial public offering of 1,415,095…

July 12, 2023 | Read More